Handbook of Therapeutic Antibodies, 2nd Edition

 Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. 

Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index.

Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.

VOLUME I: DEFINING THE RIGHT ANTIBODY COMPOSITION

Therapeutic Antibodies - From Past to Future
Stefan Dübel

PART 1: SELECTING AND SHAPING THE ANTIBODY MOLECULE

Selection Strategies I: Monoclonal Antibodies
Gerhard Moldenhauer

Selection Strategies II: Antibody Phage Display
Michael Hust, Andre Frenzel, Florian Tomszak, Jonas Köller

Transgenic Animals Derived by DNA Microinjection
Marianne Brüggemann, Michael J. Osborn, Biao Moa, Suzanne Avis, Ignacio Anegon, Roland Bülow

Molecular Engineering I: Humanisation Strategies
Jose Saldanha

Antibody Affinity
Andre Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, Larry Green

Molecular Engineering III: Fc
Thomas Valerius, Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner

Glycosylation of Antibody Molecules
Roy Jefferis

Bioinformatics Tools for Analysis of Antibodies
Andrew C. R. Martin, James Allen

How to use IMGT for Therapeutic Antibody Engineering
Marie-Paul Lefranc

PART 2: MODIFIED ANTIBODIES

Bispecific Antibodies
Roland E. Kontermann, Dafne Müller

Single Domain Antibodies: An Overview
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, B. Hamilton

Antibody-Drug Conjugates (ADCs): New Frontier in Cancer Therapeutics
Ravi Chari, Rajeeva Singh, John M. Lambert

Antibody Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins
Jürgen Krauss, Athanasios Mavratzas, Michaela A. E. Arndt, Stefan Kiesgen

PART 3: EMERGING TECHNOLOGIES

Emerging Technologies for Antibody Selection
Mike Taussig, Mingyue He

Anti-idiotypic Antibodies
Alejandro Lopez-Requena, Oscar Roberto Burrone, Rolando Perez

Non-antibody Scaffolds as Alternative Therapeutic Agents
Arne Skerra, Markus Fiedler

Antibody Directed Enzyme Prodrug Therapy (ADEPT)
Surinder K. Sharma, Kerry A. Chester, Kenneth D. Bagshawe

Engineered Antibody Domains as Candidate Therapeutics
Weizao Chen, Ponraj Prabakaran, Dimiter S. Dimitrov

Chimeric Antigen Receptors - "CARs"
Thomas Schirrmann, Ulf Petrausch

Emerging Alternative Production Systems
Thomas Jostock, Benjamin Sommer, Holger Laux, Andre Frenzel

VOLUME II: CLINICAL DEVELOPMENT OF ANTIBODIES

PART 4: THE WAY INTO THE CLINIC

Process Development and Manufacturing of Therapeutic Antibodies
Hitto Kaufmann, Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser

The Immunogenicity of Therapeutic Antibodies
Melody Sauerborn

Biosimilar Monoclonal Antibodies
Susanne D. Pippig, Carsten Brockmeyer, Robert E. Zoubek

Patent Issues Relating to Therapeutic Antibodies
Michael Braunagel, Barbara Rigby, Deborah Owen

PART 5: THERAPEUTIC ANTIBODY PIPELINE

Monoclonal Antibodies in Phase III Clinical Trials
Peter Markus Deckert, Ulf Petrausch

Antibodies in Early Phase Clinical Studies: Cancer Therapy
Anthony Olszanski, Matthew Zibelman, Hossein Borghaei

Targeting Angiogenesis by Therapeutic Antibodies
Thomas Effert, Onat Kadioglu, Ean Jeong Seo

Antibodies in Phase 3: Immunological Disorders
Penelope Ward, Mark Bodmer

Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders
Frank Brennan

MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders
Frank Brennan

T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

B Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

mAbs Targeting Apoptosis, Angiogenesis Inhibitors and other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders
Frank Brennan

Antibodies in Clinical Study: Infectious Diseases
Guillaume Descoubeaux

Immunotherapeutics for Neurological Disorders
Anne Messer, Kevin Manley, Cynthia A. Lemere

PART 6: GAINING MARKETING APPROVAL

Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy
Marjorie A. Shapiro, Patrick G. Swann, Stacey Ricci

Regulatory Review: Clinical to Market Transition
Gabriele Dallmann

Monoclonal antibody nomenclature for clinical studies (USA)
Stephanie Shubat

VOLUME III: APPROVED THERAPEUTIC ANTIBODIES

PART 7: APPROVED THERAPEUTIC ANTIBODIES

Oligoclonal and Polyclonal Antibody Preparations
Mark C. Glassy, Rishab K. Gupta

Adalimumab (Humira)
Janice Reichert

Alemtuzumab (Lemtrada, MabCampath)
Janice Reichert, Thomas Elter, Michael Hallek

Basiliximab and Daclizumab
Nasimul Ahsan, Burcin Taner, Nadim Mahmud

Belimumab (Benlysta)
David P. D´Cruz, Pamela M.K. Lutalo, Natasha Jordan, Thi-Sau Migone

Brentuximab vedotin (Adcetris)
Neils van de Donk

Canakinumab (ILARIS)
Hermann Gram

Catumaxomab (Removab) - Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination
Horst Lindhofer, M. Stanglmaier, R. Buhmann, M. Jäger, D. Klunker, P. Ruf, J. Hess

Cetuximab (Erbitux)
Sonja Wilke, Michael Hust

Denosumab (Prolia)
Torsten Meyer

Efalizumab (Raptiva)
Karlheinz Schmitt-Rau

Calicheamycin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin
Martin Gramatzki, Matthias Peipp

Golimumab (Simponi)
Janice Reichert, Sohini Mazumdar

Yttrium-90 Ibritumomab Tiuxetan (Zevalin)
Karin Hohloch, Björn Chapuy, Lorenz Trümper

Infliximab (Remicade)
Christian Antoni

Ipilimumab (Yervoy)
Javier Puente, Teresa Alonso Gordoa, Eduardo Diaz-Rubio

Muromonab-CD3 (Orthoclone OKT3)
Janice Reichert, Harald Becker

Nimotuzumab: A Humanized Anti-EGFR Antibody
Tania Crombet

Obinutuzumab
Christian Klein, Marina Bacac, Pablo Umana, Michael Wenger

VOLUME IV: APPROVED THERAPEUTIC ANTIBODIES AND IN VIVO DIAGNOSTICS

Ofatumumab: A Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity
Ronald P. Taylor, Margaret A. Lindorfer, Joost Bakker, Paul Parren

Omalizumab (Xolair) - Anti-Immunoglobulin E Treatment in Allergic Diseases
Klaus Kroegel, Martin Foerster

Palivizumab
Louis Bont

Panitumumab (Vectibix) - A Treatment for Metastatic Colorectal Cancer
Jonas Kügler

Pertuzumab (Perjeta)
Jose Angel Garcia-Saenz, Fernando Moreno Anton, Coralia Bueno Muino

Ranibizumab (Lucentis): A New Anti-angiogenic Treatment in Ophthalmology
Nicolas Leveziel, Marc Ohresser, Gilles Paintaud

Raxibacumab - Human Monoclonal Antibody Against Anthrax Toxin
Sally Bolmer, Thi-Sau Migone

Rituximab (Rituxan)
Stefan Dübel, Axel Boehnke, Michael Wenger

Tocilizumab (Actemra)
Graeme Jones

Trastuzumab (Herceptin) and Ado-Trastuzumab Emtansine (T-DM1)
M. H. Ruhe Chowdhury, Paul Ellis

Ustekinumab (Stelara)
Stefan Dübel, Oya Cingoz, Janice Reichert

Abciximab, Bevacizumab, Certolizumab pegol, Eculizumab, Natalizumab
Janice Reichert

Itolizumab (Alzumab), Mogamulizumab (Poteligeo) and Tositumomab (Bexxar)
Stefan Dübel

PART 8: IN VIVO DIAGNOSTICS

Radiolabeled Antibodies for Diagnostic Imaging
Christopher J. Palestro

Appendix

Index